

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN-04082	Serial No.: 09/470,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)  (37 CFR § 1.98(b))		Applicant: Couto <i>et al.</i>		
		Filing Date: 12/22/99	Group Art Unit: 1633	
DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
1	Connelly <i>et al.</i> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 88(10):3846-3853 (1996)			
2	Connelly <i>et al.</i> , "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> 91(9):3273-3281 (May 1, 1998)			
3	Lozier <i>et al.</i> , "Gene Therapy and the Hemophilias," <i>JAMA</i> 271(1):47-51 (1994)			
4	Snyder <i>et al.</i> , "Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene Transfer of Recombinant AAV Vectors," <i>Nature Genetics</i> 16:270-276 (July 1997)			
5	Zatloukal <i>et al.</i> , "In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> 91:5148-5152 (1994)			
Examiner:	<i>[Signature]</i>		Date Considered:	<i>10/31/00</i>
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			